Clinical Trials Using Ulixertinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Ulixertinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Location: 1209 locations
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.
Location: 4 locations
Ulixertinib and Hydroxychloroquine for the Treatment of Advanced MAPK-Mutated Gastrointestinal Cancers
This phase I trial identifies side effects, activity, and best dose of ulixertinib when given together with hydroxychloroquine in treating patients with MAPK gene mutated gastrointestinal cancer that has spread to other places in the body (advanced). MAP kinase (MAPK) gene products are involved in a wide variety of cellular processes such as proliferation and differentiation. Ulixertinib may stop the growth of tumor cells by blocking some of the MAPK gene products needed for cell growth. Hydroxychloroquine is used to decrease the body's immune response and may result in tumor cell death. Giving ulixertinib and hydroxychloroquine may shrink tumors in patients with gastrointestinal cancer.
Location: Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah
Ulixertinib and Palbociclib in Treating Patients with Advanced or Refractory Solid Tumors or Metastatic Pancreatic Cancer
This phase I trial studies the side effects and best dose of ulixertinib and palbociclib and to see how well they work in treating patients with solid tumors that have spread to other places in the body or do not respond to treatment or pancreatic cancer that has spread to other places in the body. Ulixertinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Ulixertinib in Treating Patients with Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.
Location: 109 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Location: 161 locations